Olga Kholmanskikh, MD, PhD, is a clinical assessor at the Federal Agency for Medicines and Health Products (FAMHP) since 2012. She is an MD by training and holds PhD in Biomedical and Pharmaceutical Sciences. She is a member of the EMA’s Companion Diagnostic (CDx) Expert Group, Oncology, Methodology and Scientific Advice Working Parties as well as an alternate member at the Committee for Advanced Therapies (CAT).